<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117676">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01921569</url>
  </required_header>
  <id_info>
    <org_study_id>AFLATEP001</org_study_id>
    <nct_id>NCT01921569</nct_id>
  </id_info>
  <brief_title>Micronized Dehydrated Human Amniotic Membrane Suspension in the Treatment of Lateral Epicondylitis</brief_title>
  <official_title>Micronized Dehydrated Human Amniotic Membrane (dHACM) Suspension in the Treatment of Lateral Epicondylitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether micronized dehydrated human amniotic
      membrane (dHACM) suspension is more effective in reducing inflammation than conservative
      measures alone when used to treat acute/early lateral epicondylitis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of patients achieving improvement in ASES elbow score in the dHACM treatment group vs the control group.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving improvement in range of motion in the dHACM treatment group vs the control group.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain scores</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Epicondylitis, Lateral Humeral</condition>
  <arm_group>
    <arm_group_label>dHACM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of Care Therapy plus dHACM injection at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of Care Therapy plus normal saline injection instead of active agent at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard of Care Therapy</intervention_name>
    <description>Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.</description>
    <arm_group_label>dHACM</arm_group_label>
    <arm_group_label>Saline Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dHACM Injection</intervention_name>
    <description>Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.</description>
    <arm_group_label>dHACM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline Injection</intervention_name>
    <description>Injection into affected area with 1.0 cc normal saline solution instead of active agent.</description>
    <arm_group_label>Saline Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old.

          -  Medicare patients may be selected.

          -  Both male and female patients will be selected.

          -  A negative x-ray of the elbow

          -  Diagnosis of lateral epicondylitis by history and exam with symptoms for no longer
             than one year.

          -  Females of childbearing potential must be willing to use acceptable methods of
             contraception (birth control pills, barriers, or abstinence).

          -  Patient understands and is willing to participate in the clinical study and can
             comply with weekly visits and the follow-up regimen.

          -  Patient has read and signed the IRB/IEC approved Informed Consent Form before
             screening procedures are undertaken.

        Exclusion Criteria:

          -  Prior surgery at the site

          -  Site exhibits clinical signs and symptoms of infection.

          -  History of chronic soft tissue inflammation of more than 6 months.

          -  A positive X-ray for fracture or significant anatomic abnormality including fracture,
             advanced arthritis, excessive calcification, etc.

          -  No history of corticosteroid injection within the past 30 days.

          -  Joint instability

          -  No rheumatologic conditions involving the elbow.

          -  No evidence of significant neurological entrapment or neurological disease of the
             forearm

          -  Concurrent cervical radiculopathy

          -  The presence of comorbidities that can be confused with or can exacerbate the
             condition including:

               -  Previous elbow trauma

               -  Previous elbow surgery

          -  Patients with a history of more than two weeks treatment with immuno-suppressants
             (including systemic corticosteroids), cytotoxic chemotherapy within one month prior
             to initial screening, or who receive such medications during the screening period, or
             who are anticipated to require such medications during the course of the study. (i.e.
             a one month &quot;washout period&quot; for these drugs.)

          -  Patients on any investigational drug(s) or therapeutic device(s) within 30 days
             preceding screening.

          -  History of radiation at the site.

          -  Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.

          -  Patients who are unable to understand the aims and objectives of the trial.

          -  Presence of any condition(s) which seriously compromises the subject's ability to
             complete this study, or has a known history of poor adherence with medical treatment.

          -  Pregnant or breast feeding.  No pregnancy within the past 6 months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Kremchek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beacon Orthopaedics &amp; Sports Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beacon Orthopaedics &amp; Sports Medicine</name>
      <address>
        <city>Sharonville</city>
        <state>Ohio</state>
        <zip>45241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 21, 2013</lastchanged_date>
  <firstreceived_date>July 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dehydration</mesh_term>
    <mesh_term>Tennis Elbow</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
